Pseudomonas Infections

"Pseudomonas Infections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Infections with bacteria of the genus PSEUDOMONAS.

Descriptor ID	D011552
MeSH Number(s)	C01.252.400.739
Concept/Terms	Pseudomonas Infections Pseudomonas Infections Infections, Pseudomonas Infection, Pseudomonas Pseudomonas Infection Pseudomonas aeruginosa Infection Pseudomonas aeruginosa Infection Pseudomonas aeruginosa Infections

Below are MeSH descriptors whose meaning is more general than "Pseudomonas Infections".

Diseases [C]
Bacterial Infections and Mycoses [C01]
Bacterial Infections [C01.252]
Gram-Negative Bacterial Infections [C01.252.400]
Pseudomonas Infections [C01.252.400.739]

Below are MeSH descriptors whose meaning is related to "Pseudomonas Infections".

Below are MeSH descriptors whose meaning is more specific than "Pseudomonas Infections".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pseudomonas Infections" by people in this website by year, and whether "Pseudomonas Infections" was a major or minor topic of these publications.

Bar chart showing 65 publications over 26 distinct years, with a maximum of 7 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	3	0	3
1998	0	1	1
1999	1	0	1
2000	1	0	1
2002	1	1	2
2003	0	3	3
2004	1	1	2
2005	2	1	3
2007	2	0	2
2008	1	0	1
2009	1	2	3
2010	1	1	2
2011	2	0	2
2012	2	0	2
2013	1	0	1
2014	2	1	3
2015	4	0	4
2016	1	1	2
2017	5	2	7
2018	2	1	3
2019	1	4	5
2020	0	1	1
2021	2	0	2
2022	3	0	3
2023	4	0	4
2024	1	1	2

Below are the most recent publications written about "Pseudomonas Infections" by people in Profiles.

Karlowsky JA, Wise MG, Hackel MA, Six DA, Uehara T, Daigle DM, Pevear DC, Moeck G, Sahm DF. Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22. J Antimicrob Chemother. 2024 12 02; 79(12):3116-3131.

View in: PubMed
Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021. Eur J Clin Microbiol Infect Dis. 2024 Jul; 43(7):1343-1348.

View in: PubMed
Karlowsky JA, Wise MG, Hsieh TC, Lu HC, Chen WT, Cheng MH, Siddiqui F, Young K, Motyl MR, Sahm DF. Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan-SMART 2012-2021. J Glob Antimicrob Resist. 2023 09; 34:106-112.

View in: PubMed
Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020. Int J Antimicrob Agents. 2023 May; 61(5):106772.

View in: PubMed
Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020. J Med Microbiol. 2023 Feb; 72(2).

View in: PubMed
Lob SH, Hawser SP, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020. Eur J Clin Microbiol Infect Dis. 2023 Mar; 42(3):365-370.

View in: PubMed
Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020. Int J Infect Dis. 2022 Dec; 125:250-257.

View in: PubMed
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922.

View in: PubMed
Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. J Med Microbiol. 2022 Apr; 71(4).

View in: PubMed
Lob SH, Kazmierczak KM, Chen WT, Siddiqui F, DeRyke CA, Young K, Motyl MR, Sahm DF. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019. J Glob Antimicrob Resist. 2022 06; 29:527-533.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement